PharmEasy Valuation Slashed 92% From Peak In Latest Janus Henderson Filing

PharmEasy Valuation Plummets 92% in Latest Janus Henderson Filing.

Expert Analysis:

• Valuation Reduction: API Holdings Pvt. (PharmEasy) valuation was cut by 92% to $460 million by Janus Henderson.

• Valuation Drop: At the end of 2021, Janus Henderson valued PharmEasy at approximately $5.6 billion In the latest SEC filing, the value of these shares has dropped by 92%, reducing PharmEasy's worth to around $460 million.

• Earlier Valuation Slash: The struggling e-pharmacy experienced a 90% reduction from its peak valuation in April this year when it raised Rs 1,800 crore, led by Ranjan Pai's Manipal Education and Medical Group and existing investors.

• Revenue Growth: FY23 revenue increased 16% to Rs 6,644 crore, up from Rs 5,728.8 crore in FY22.

• Losses Widened: The Company Losses widened to Rs 5,211.7 crore from Rs 3,992.4 crore in FY22. It faces increased competition from rivals like Tata 1mg, Medlife, Flipkart Health+, and Reliance-backed Netmeds.